6 Results for "

AlphaScreen assay

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "AlphaScreen assay" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-103663
CAS No.: 1951408-58-4
Purity:  99.18%
Research Areas:  

Cancer

MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117233
CAS No.: 1500080-17-0
Purity:  99.63%
Target:  

β-catenin Wnt

Research Areas:  

Metabolic Disease Cancer

UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .
loading...
    loading...
Cat. No.: HY-103663A
CAS No.: 2170606-94-5
Research Areas:  

Cancer

MAK683 hydrochloride is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .
loading...
    loading...
Cat. No.: HY-142743
CAS No.: 2223014-57-9
Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC50s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-103663R
CAS No.: 1951408-58-4
Research Areas:  

Cancer

MAK683 (Standard) is the analytical standard of MAK683 (HY-103663). This product is intended for research and analytical applications. MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .
loading...
    loading...
Cat. No.: HY-183248
Research Areas:  

Cancer

BRDT-IN-2 is a BRDT-BD1-preferring inhibitor (Ki=10 μM) with higher affinity for BRDT-BD1 than BRD4-BD1. BRDT-IN-2 preferentially binds BRDT-BD1 without direct interaction with BRDT-BD1’s Arg54 residue. BRDT-IN-2 binds BRD4-BD1 with lower affinity via structured water molecule displacement in its binding pocket. BRDT-IN-2 can be used for the research of multiple myeloma .
loading...
    loading...